Theravance Biopharma Inc (0TB) — Long-term Investment Intensity

Latest as of September 2025: 0.7%

Theravance Biopharma Inc (0TB) has a Long-term Investment Intensity of 0.7% as of September 2025. Long-term investments of €3.03 Million represent 0.7% of total assets of €415.46 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. See Theravance Biopharma Inc shareholders equity for net asset value and shareholders' equity analysis.

LT Investment Intensity

0.7%
LT Investments / Total Assets

Long-term Investments

€3.03 Million
EUR

Total Assets

€415.46 Million
EUR

Country

Germany
F

Theravance Biopharma Inc Long-term Investment Intensity (2014–2021)

This chart shows how Theravance Biopharma Inc's Long-term Investment Intensity has evolved across 8 annual periods from 2014 to 2021. As of September 2025, the intensity stands at 0.7%, reflecting long-term investments of €3.03 Million against total assets of €415.46 Million EUR. Also explore Theravance Biopharma Inc assets under control for the complete picture of this company's asset base.

Annual Long-term Investment Intensity for Theravance Biopharma Inc (2014–2021)

The table below presents the year-by-year Long-term Investment Intensity for Theravance Biopharma Inc from 2014 to 2021, covering 8 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see Theravance Biopharma Inc market capitalisation.

Year LT Investment Intensity LT Investments (EUR) Total Assets Change (pp)
2021 18.0% €67.54 Million €374.82 Million ▲ +15.3 pp
2020 2.7% €12.75 Million €469.06 Million ▲ +1.5 pp
2019 1.2% €4.99 Million €408.83 Million ▼ -0.9 pp
2018 2.1% €11.87 Million €560.24 Million ▼ -7.3 pp
2017 9.4% €41.59 Million €441.40 Million ▼ -6.2 pp
2016 15.6% €99.56 Million €639.25 Million ▼ -1.4 pp
2015 16.9% €50.86 Million €300.12 Million ▲ +1.7 pp
2014 15.2% €51.40 Million €337.77 Million
pp = percentage points